We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients.
- Authors
Atzpodien, Jens; Terfloth, Kerstin; Fluck, Michael; Reitz, Martina
- Abstract
The efficacy of cisplatin, gemcitabine, and treosulfan (CGT) was evaluated in patients with chemotherapy pretreated relapsed AJCC stage IV uveal malignant melanoma. Patients received i.v./intrahepatic cisplatin, i.v. gemcitabine, and i.v. treosulfan (CGT) on day 1 and 8 as first-line ( n = 1), second-line ( n = 9), third-line ( n = 1) or fourth-line ( n = 1) therapy. Cisplatin, gemcitabine, and treosulfan (CGT)-therapy was repeated every 5 weeks until progression of disease occurred. A maximum of six CGT-cycles (mean, 2 cycles) was administered per patient. No objective response was observed, six patients (50%) had stable disease and six (50%) patients progressed upon first reevaluation. Overall survival of all the 12 patients was 6 months. Patients with stable disease reached a median overall survival of 12 months, while patients with disease progression upon first reevaluation had a median overall survival of 4 months, only. Grade III/IV related hematotological side effects were experienced in six (leukopenia) and four (thrombocytopenia) patients. Treatment with CGT may lead to disease stabilization and prolonged survival in a substantial proportion of progressive stage IV uveal melanoma patients, even following heavy chemotherapy treatment.
- Subjects
CISPLATIN; DRUG therapy; UVEA cancer; MELANOMA; THERAPEUTICS; THROMBOCYTOPENIA
- Publication
Cancer Chemotherapy & Pharmacology, 2008, Vol 62, Issue 4, p685
- ISSN
0344-5704
- Publication type
Article
- DOI
10.1007/s00280-007-0655-9